A phase I first-in-human study of TRC105 (anti-endoglin antibody) in patients with advanced cancer

Clinical Cancer Research

Volumn 18, Issue 17, 2012, Pages 4820-4829

  Rosen, Lee S ^a   Hurwitz, Herbert I ^b   Wong, Michael K ^c,h   Goldman, Jonathan ^a   Mendelson, David S ^d   Figg, William D ^e   Spencer, Shawn ^f   Adams, Bonne J ^g   Alvarez, Delia ^g   Seon, Ben K ^c   Theuer, Charles P ^g   Leigh, Bryan R ^g   Gordon, Michael S ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d Pinnacle Oncology Hematology   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f SAIC FREDERICK INC   (United States)

^g TRACON Pharmaceuticals   (United States)

^h UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G1 ANTIBODY; TRC 105; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER GROWTH; CHO CELL; CLINICAL ARTICLE; COLORECTAL CANCER; CONSTIPATION; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EXPOSURE; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EPISTAXIS; FATIGUE; FEMALE; GASTROINTESTINAL HEMORRHAGE; GINGIVA BLEEDING; HUMAN; IMMUNOGENICITY; INFUSION RELATED REACTION; KIDNEY CANCER; LUNG CANCER; MALAISE; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; NAUSEA; OVARY CANCER; PAIN; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; SARCOMA; SOLID TUMOR; TELANGIECTASIA; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; DRUG ADMINISTRATION SCHEDULE; DRUG TOXICITY; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; RECEPTORS, CELL SURFACE; TREATMENT OUTCOME;

EID: 84865766360     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-0098     Document Type: Article

References (34)

1. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003;9:653-60.
2. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992;267:10931-4.
3. Escudier B, Bellmunt J, Négrier S, Bajetta E, Melichar B, Bracarda S, et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 2010;28:2144-50.
4. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
5. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008:359:378-90.
6. Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23:792-9.
7. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50.
8. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27:4733-40.
9. Seon BK, Haba A, Matsuno F, Takahashi N, Tsujie M, She X, et al. Endoglin-targeted cancer therapy. Curr Drug Deliv 2011;8:135-43.
10. Sánchez-Elsner T, Botella LM, Velasco B, Langa C, Bernabéu C, et al. Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-beta pathways. J Biol Chem 2002;277:43799-808.
11. Bockhorn M, Tsuzuki Y, Xu L, Frilling A, Broelsch CE, Fukumura D, et al. Differential vascular and transcriptional responses to anti-vascular endothelial growth factor antibody in orthotopic human pancreatic cancer xenografts. Clin Cancer Res 2003;9:4221-6.
12. Davis DW, Inoue K, Dinney CP, Hicklin DJ, Abbruzzese JL, McConkey DJ, et al. Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts. Cancer Res 2004;64:4601-10.
13. Li DY, Sorensen LK, Brooke BS, Urness LD, Davis EC, Taylor DG, et al. Defective angiogenesis in mice lacking endoglin. Science 1999;284: 1534-7.
14. Lenato GM, Guanti G. Hereditary haemorrhagic telangiectasia (HHT): genetic and molecular aspects. Curr Pharm Des 2006;12: 1173-93.
15. Duff SE, Li C, Garland JM, Kumar S. CD105 is important for angiogenesis: evidence and potential applications. FASEB J 2003;17: 984-92.
16. Dallas NA, Samuel S, Xia L, Fan F, Gray MJ, Lim SJ. Endoglin (CD105): a marker of tumor vasculature and potential target for therapy. Clin Cancer Res 2008;14:1931-7.
17. Takahashi N, Haba A, Matsuno F, Seon BK. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide. Cancer Res 2001;61:7846-54.
18. Uneda S, Toi H, Seon BK. Anti-endoglin monoclonal antibodies are effective for suppressing metastasis and the primary tumors by targeting tumor vasculature. Int J Cancer 2009;125:1446-53.
19. Theuer CP, Myszka D, Sherwood S, Incardona F, Haughey D, Benedict S, et al. Preclinical pharmacokinetic & pharmacodynamic data for TRC105 (Anti-Endoglin Antibody) are consistent with clinical activity observed at low doses in patients with advanced cancer. In Annual Meeting of the American Association for Cancer Research, Abstract #12372009, 2009.
20. Shiozaki K, Harada N, Greco WR, Haba A, Uneda S, Tsai H, et al. Antiangiogenic chimeric anti-endoglin (CD105) antibody: pharmacokinetics and immunogenicity in nonhuman primates and effects of doxorubicin. Cancer Immunol Immunother 2006;55:140-50.
21. Duffaud F, Therasse P. New guidelines to evaluate the response to treatment in solid tumors. Bull Cancer 2000;87:881-6.
22. Rokhlin OW, Cohen MB, Kubagawa H, Letarte M, Cooper MD, et al. Differential expression of endoglin on fetal and adult hematopoietic cells in human bone marrow. J Immunol 1995;154:4456-65.
23. Guttmacher AE, Marchuk DA, White RI Jr. Hereditary hemorrhagic telangiectasia. N Engl J Med 1995;333:918-24.
24. Bendell JC, Gordon MS, Hurwitz H, Condon CH, Wilson D, Yang Y, et al. A phase 1 dose escalation study of ACE-041, a novel inhibitor of ALK1-mediated angiogenesis, in patients with advanced solid tumors, in American Society of Clinical Oncology 2011: Chicago, IL.
25. Goff LW, Cohen RB, Berlin J, Noberasco C, Borghaei H, Gallo-Stampino C, et al. Phase I study of PF-03446962, a fully human mAb against ALK1, a TGF-beta receptor involved in tumor angiogenesis, in American Society of Clinical Oncology 2011: Chicago, IL.
26. Brinkerhoff BT, Poetker PD, Choong NW. Long-term therapy with bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med 2011;364:688-9.
27. Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse MCH, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3- galactose. N Engl J Med 2008;358:1109-17.
28. Dillman RO, Hendrix CS. Unique aspects of supportive care using monoclonal antibodies in cancer treatment. Support Cancer Ther 2003;1:38-48.
29. Bock AJ, Tuft Stavnes H, Kærn J, Berner A, Staff AC, Davidson B. Endoglin (CD105) expression in ovarian serous carcinoma effusions is related to chemotherapy status. Tumour Biol 2011;32: 589-96.
30. Haruta Y, Seon BK. Distinct human leukemia-associated cell surface glycoprotein GP160 defined by monoclonal antibody SN6. Proc Natl Acad Sci U S A 1986;83:7898-902.
31. Altomonte M, Montagner R, Fonsatti E, Colizzi F, Cattarossi I, Brasoveanu LI, et al. Expression and structural features of endoglin (CD105), a transforming growth factor beta1 and beta3 binding protein, in human melanoma. Br J Cancer 1996;74:1586-91.
32. Bussolati B, Bruno S, Grange C, Ferrando U, Camussi G. Identification of a tumor-initiating stem cell population in human renal carcinomas. FASEB J 2008;22:3696-705.
33. Hedvat CV, Comenzo RL, Teruya-Feldstein J, Olshen AB, Ely SA, Osman K, et al. Insights into extramedullary tumour cell growth revealed by expression profiling of human plasmacytomas and multiple myeloma. Br J Haematol 2003;122:728-44.
34. Hong H, Yang Y, Zhang Y, Engle JW, Barnhart TE, Nickles RJ, et al. Positron emission tomography of CD105 expression during tumor angiogenesis. Eur J Nucl Med Mol Imaging 2011;38: 1335-43.